Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Apax Global Alpha to invest €8m in IANS

(Sharecast News) - Investment firm Apax Global Alpha said on Wednesday that it intends to invest roughly €8.0m in order to acquire research and advisory services business IANS.

Apax Global Alpha said it has reached a definitive agreement to acquire IANS, with the transaction expected to close in Q2, subject to customary closing conditions.

The London-listed group stated the partnership will enable IANS to accelerate product development, expand its value proposition, and scale its go-to-market efforts, which will help the company meet the increasing demand for InfoSec decision support services and strengthen its leadership position in the market.

"Note that AGA's expected investment in IANS is calculated based on the look-through positions of ADF II's overall investment in IANS and is translated based on the latest exchange rates available where applicable," added Apax Global.

As of 1015 BST, Apax Global Alpha shares were up 0.71% at 142.0p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

UBS to book $900m provision over Greensill supply financing funds
(Sharecast News) - Swiss banking giant UBS announced on Monday that it expected to book a provision of about $900m related to Credit Suisse's funds, tied to the collapsed supply chain financing firm Greensill Capital.
Citi downgrades European equities to 'neutral'
(Sharecast News) - Citi downgraded its stance on European equities on Monday to 'neutral' from 'overweight' as it said near-term risks have increased, with markets narrowing and political uncertainty taking centre stage.
Hutchmed publishes positive sovleplenib trial results
(Sharecast News) - Hutchmed China announced the publication of positive results from its phase three 'ESLIM-01' trial of sovleplenib in the Lancet Haematology.
Somero trading in line with expectations
(Sharecast News) - Somero Enterprises said in an update on Monday that trading for the first five months of 2024 was consistent with expectations.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.